Climb Bio, Inc. (CLYM) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CLYM currently has 57.3M outstanding shares. with significant dilution risk as 57.3M authorized shares could dilute existing holders by 100.0%. The company has significantly diluted shareholders by 144.12% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 29, 2026 |
S-3 filing: This prospectus relates to the resale of up to 11,587,000 shares of common stock by selling stockholders, consisting of 9,481,000 outstanding shares and 2,106,000 shares issuable upon the exercise of prefunded warrants. |
57M | 57M |
| May 07, 2026 |
10-Q filing | 57.3M shares outstanding |
57M | 43M |
| Nov 06, 2025 |
10-Q filing | 68.0M shares outstanding |
68M | 43M |
| Aug 12, 2025 |
10-Q filing | 67.6M shares outstanding |
68M | 43M |
| May 14, 2025 |
10-Q filing | 67.5M shares outstanding |
67M | 43M |
| Mar 25, 2025 |
10-K filing | 67.5M shares outstanding |
67M | 43M |
| Nov 12, 2024 |
10-Q filing | 67.0M shares outstanding |
67M | 43M |
| Nov 12, 2024 |
S-3 filing: The company may offer and sell debt securities, common stock, preferred stock and subscription rights from time to time in one or more offerings of up to $200,000,000 in aggregate offering price. |
67M | 43M |
| Aug 14, 2024 |
10-Q filing | 67.1M shares outstanding |
67M | 43M |
| Jul 12, 2024 |
S-3 filing: Registration for resale of 36,798,329 shares of common stock by selling stockholders. |
28M | 43M |
| May 15, 2024 |
10-Q filing | 27.6M shares outstanding |
28M | 6M |
| Mar 28, 2024 |
10-K filing | 27.0M shares outstanding |
27M | 6M |
| Nov 14, 2023 |
10-Q filing | 27.1M shares outstanding |
27M | 6M |
| Aug 10, 2023 |
10-Q filing | 26.8M shares outstanding |
27M | 6M |
| May 11, 2023 |
10-Q filing | 26.5M shares outstanding |
26M | 6M |
| Mar 06, 2023 |
10-K filing | 26.3M shares outstanding |
26M | 6M |
| Nov 14, 2022 |
10-Q filing | 26.3M shares outstanding |
26M | 6M |
| Aug 15, 2022 |
10-Q filing | 26.3M shares outstanding |
26M | 6M |
| May 16, 2022 |
10-Q filing | 26.2M shares outstanding |
26M | 6M |
| Mar 07, 2022 |
10-K filing | 26.6M shares outstanding |
27M | 6M |
| Nov 08, 2021 |
10-Q filing | 26.6M shares outstanding |
27M | 6M |
| Sep 13, 2021 |
10-Q filing | 26.5M shares outstanding |
27M | 6M |
| Aug 09, 2021 |
S-1/A filing: This is the initial public offering of Eliem Therapeutics, Inc. offering 6,000,000 shares of their common stock at an expected price of $12.50 per share. |
25M | 6M |
| Aug 09, 2021 |
S-1/A filing: This is an S-1/A filing detailing recent sales of unregistered securities since January 1, 2018, including issuances of common and preferred stock, option grants, and restricted stock purchase awards. |
23M | 6M |
| Aug 03, 2021 |
S-1/A filing: This is the initial public offering of Eliem Therapeutics, Inc. We are offering 4,500,000 shares of our common stock. The initial public offering price is expected to be between $17.00 and $19.00 per share. |
23M | 4.5M |
| Aug 02, 2021 |
S-1/A filing: Eliem Therapeutics, Inc. is offering 4,500,000 shares of common stock in its initial public offering. The initial public offering price is expected to be between $17.00 and $19.00 per share. |
23M | 4.5M |
| Jul 16, 2021 |
S-1 filing: This is the initial public offering of Eliem Therapeutics, Inc. offering shares of common stock. |
38M | 0 |